Compare · Head-to-head
CJC-1295 vs Semaglutide.
Evidence, risk, regulatory flags, cost, and vendor coverage compared side by side. We don’t sell peptides — we help you choose between them.
Which should you research first?
Start with Semaglutide, then use the table to confirm fit.
Semaglutide is the cleaner first read based on the current evidence, risk, and regulatory data stored for this pair. The right answer can still change if your goal, sport testing status, vendor constraints, or monitoring tolerance makes the other option a better fit.
Comparison next step
Personalize this head-to-head.
Take the quiz before converting a comparison into a compound, vendor, or protocol decision.
01 · At a glance
| Decision factor | CJC-1295 | Semaglutide |
|---|---|---|
| Primary fit | muscle growth & strength and fat loss & metabolism comparisons | fat loss & metabolism research where you want a clear starting point |
| Evidence | Tier B | Tier A |
| Risk | high | medium |
| Experience level | intermediate | intermediate |
| Budget tier | mid | premium |
| Administration route | subcutaneous | subcutaneous, oral |
02 · Use case & timing
| Decision factor | CJC-1295 | Semaglutide |
|---|---|---|
| Goal fit | Muscle Growth & Strength, Fat Loss & Metabolism, GH Axis Optimization | Fat Loss & Metabolism |
| What users compare it for | Sustained GH and IGF-1 elevation; body composition modulation (long-horizon, not well-established for consumer outcomes). | Clinically meaningful appetite reduction, HbA1c improvement, and substantial body-weight reduction in approved-use populations. |
| Onset timeline | Biomarker effects persist multiple days; IGF-1 elevations up to ~2 weeks after single dose. | Glucose effects emerge over the first weeks; weight-loss effects build across 3 to 12 months. |
| Main tradeoff | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. |
03 · Safety & restrictions
| Decision factor | CJC-1295 | Semaglutide |
|---|---|---|
| Adverse effects | Injection-site reactions, headache, diarrhea, flushing, transient hypotension at higher doses. | Common GI adverse effects include nausea, vomiting, diarrhea, and constipation. Gallbladder and pancreatitis concerns exist, and thyroid C-cell tumor warning remains part of class labeling. |
| Contraindications | GH-axis stimulation risks: glucose intolerance, theoretical neoplasia concerns with elevated IGF-1. | Avoid in personal or family history of medullary thyroid carcinoma or MEN2. Use caution with pancreatitis history, severe gastroparesis, pregnancy, and concurrent insulin/sulfonylureas. |
| Interaction notes | Monitor insulin/glucose sensitivity, thyroid axis, and cortisol/prolactin. Trials report no significant cortisol/prolactin/TSH/LH increases at 60 µg/kg single dose. | Additive hypoglycemia risk with insulin or sulfonylureas. Delayed gastric emptying can alter absorption timing for oral drugs. |
| Regulatory status | Not approved | Prescription-approved |
| FDA flag | FDA compounding caution | FDA compounding caution |
| WADA status | WADA S2 | Not listed |
04 · Age & monitoring
| Decision factor | CJC-1295 | Semaglutide |
|---|---|---|
| Supported age ranges | 25-34, 35-44, 45-54 | 25-34, 35-44, 45-54, 55-64, 65+ |
| Life-stage note | Midlife is where GH-restoration framing is most often used, but evidence and long-term safety remain limited. | Strongest fit for adults where weight, glucose control, and cardiometabolic risk are part of the decision. |
| Monitoring burden | high | medium |
| Follow-up cadence | Reassess at startup and then roughly every few months if continuing. | Early tolerance review in the first weeks, then metabolic follow-up every few months. |
05 · Cost & sourcing
| Decision factor | CJC-1295 | Semaglutide |
|---|---|---|
| Typical cycle cost | $143.98 | $120.00 |
| Estimated monthly cost | $47.99 | $120.00 |
| Cost confidence | High confidence | High confidence |
06 · Before you buy
| Decision factor | CJC-1295 | Semaglutide |
|---|---|---|
| Tracked vendor listings | 3 listings | 1 listing |
| Sourcing note | At least one listing is a blend rather than a clean standalone product, so review the product page carefully. | Product format varies by listing, so double-check route, concentration, and presentation. |
| Stack-friendly? | Usually stack-friendly | Usually stack-friendly |
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Still deciding
Get a plan tailored to you.
The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.